The market for colorectal cancer treatment is forecast to grow at a compound annual growth rate (CAGR) of 3% in the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and China, according to a report by GlobalData.
Titled ‘PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2025’, the report forecasts the colorectal cancer market to grow from $8.15bn in 2015 to $11bn by 2025, driven by aging population and rise in incidences of the disease, and the launch and increase in uptake of premium treatments for the condition.
Keytruda (pembrolizumab), an immune checkpoint inhibitor by Merck, will be the first drug of its kind to be approved for the treatment of microsatellite high-colorectal cancer and is expected to enjoy rapid uptake across the 8MM, states the report.
Furthermore, major unmet needs of colorectal cancer patients will be addressed by two second-line treatments to be launched in 2020, which include napabucasin by Sumitomo Dainippon Pharma, and the combination therapy encorafenib plus binimetinib by Array BioPharma.
According to GlobalData oncology and hematology analyst Chiara Marchetti, PhD: “The launch of these drugs will facilitate a gradual increase in the number of patients receiving branded therapy across different lines of metastatic therapy, thus increasing the patient pool of these segments and the overall colorectal cancer market size.”
Another area with significant unmet needs is resectable high-risk colorectal cancer, for which treatment through neoadjuvant / adjuvant pipeline agents is required.
Lack of premium-priced agents in this space means that the prescription of generic and relatively cheap chemotherapies will continue throughout the forecast period, adds the report.